DOCSLIB.ORG

Babraham Research Campus Case Study

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

The Babraham Research Campus – supporting the UK bioscience industry The Babraham Research Campus, near Cambridge, UK, provides around 115,000 square foot of Campus growth laboratory and office space for early-stage bioscience companies alongside the world-renowned Since it was founded in 1998 the Campus has expanded from Babraham Institute. The aim of the Campus, which was established in 1998, is to support 15,000 sq ft to more than 115,000 sq ft by 2014 new bioscience companies and catalyse the commercial exploitation of biomedical research. Companies on the site have access to research facilities, infrastructure and support services, as well Campus buildings have been 85% to 100% occupied since the Campus opened (lettable floor space in square feet, based on when buildings were officially opened). as being in close proximity to the scientific expertise at the Babraham Institute and elsewhere in the Cambridge area. The Campus is managed by Babraham Bioscience Technologies Ltd (BBT), which oversees the 1998 2006 2007 2010 2012 2013 2014 administration and development of the site. This case study shows how the Campus has developed since the bioincubator was established in 1998, and how three companies currently based on the Campus are benefitting from the facilities The Babraham Research Campus in 2014. it offers. Image: The Babraham Institute 1998 2006 2009 2011 2012 Bennett adds 20,000 sq ft (115,000 sq ft total) 1998 2006 2009 2011 2012 The Babraham bioincubator is The Minerva building is officially Bioinformatics company Eagle BBSRC sets out its strategy to The bioincubator building Moneta established. It aims to provide opened by Mr Phil Willis MP, Genomics moves to the Babraham support innovation through the is officially opened by the Minister laboratory and office space, services Chairman of the House of Commons Research Campus (see company research and innovation campuses for Universities and Science, David and expertise to new biomedical Science and Technology Select profile). associated with strategically funded Willetts12. start-up companies1. Committee. At the time, Minerva institutes. The initial focus is the housed four companies: Cambridge BBT announce plans for a new Babraham Research Campus and 2013 adds 14,500 sq ft Jonas Webb (95,500 sq ft total) 2001 Biotechnology Ltd, NovaThera Ltd, bioincubator building, Maia. Norwich Research Park. The Jonas Webb building – a new The bioincubator is fully occupied Stem Cell Sciences plc, and Cyclacel5. Construction is scheduled to begin follow-on laboratory (chemistry) by tenant companies. The in early 2010. Maia is fully let before BBSRC receives £44M for investment building - is opened by Minister bioincubation facilities are extended 2007 completion8. at the Babraham Research Campus. for Universities and Science David adds 17,500 sq ft Moneta (85,000 sq ft total) with the Building 200 series2. The second new bioincubator This includes a fifth bioincubator Willetts. 50% of the space in the building, Meditrina, is completed. It 2010 building, Moneta, two follow-on Jonas Webb building is let before 2002 is fully occupied within six months6. The Maia building is officially buildings (one chemistry, Jonas completion13. BBT are granted planning permission opened by Dr Julian Huppert MP9. Webb, one biology, Bennett Building) Maia adds 8,500 sq ft (70,000 sq ft total) for two further bioincubator Her Excellency Madame Fu Ying, for companies seeking increased 2014 buildings3. Ambassador of the People’s Republic Wellcome Trust spinout company space and to remain for longer on The Babraham Research Campus of China, officially opens the Kymab Ltd joins the Campus the campus, a new Central Scientific now has 51 companies on site, Meditrina adds 20,000 sq ft 2004 Meditrina building7. (see company profile). Services Building 580, improvements occupying 99% of the lettable Construction begins on ‘Minerva’, to infrastructure including roads space14, and more than 95 the first new bioincubator building at XiangCam TCM Research Centre and utilities and a new composting companies have benefitted from Babraham. (XiangCam), a collaboration facility10. the Campus since it opened. The between Chinese enterprise and Campus now provides around The bioincubation facilities on the academic institutions in China Construction of the Moneta building 95,500 square feet of serviced adds 20,000 sq ft Minerva Campus now house 21 companies4. and the UK, is the 50th biomedical begins. It is just over 50% let before facilities to support new bioventures, company to occupy the Babraham completion11. and continues to expand. BBT take possession of the Minerva Research Campus, as well as the first Around 15,000 sq ft (Building 405/6) building. international company on the site7. Pharmaceuticals company Mission The new Bennett Building is 88% Therapeutics Ltd moves into the let by early 2014. It is due to be 2005 newly-completed Moneta building completed in late 2014 to provide 1998 2006 2007 2010 2012 2013 2014 The first tenants move into Minerva. (see company profile). a further 20,000 sq ft of lettable laboratory and office space. 1 Kymab Ltd ymab Ltd1 joined the Babraham Research Campus in 2010. The company’s Kymouse technology is transforming the discovery and development of fully human monoclonal antibody therapeutics and Kymab Ltd is a spinout company, founded in vaccines2. Both The Wellcome Trust and The Bill and Melinda Gates Foundation — two of the world’s 2009, from the Wellcome Trust Sanger Institute K in Cambridge. The company received £20M Series largest healthcare foundations — have invested over $70 million to enable the company to create a world- class pipeline of fully human monoclonal antibodies and vaccines. A equity financing from the Wellcome Trust investment division in 2010. It is based in the Kymab’s drug discovery pipeline is focused on the Research Campus, taking advantage of the critical mass Meditrina building on the Babraham Research therapeutic areas of immune-oncology and immunology. of internationally-renowned basic research and industry Campus and, in early 2014, had 42 employees. It collaborates with others to exploit its discovery and expertise in the area south of Cambridge. development capability and fuel the drug discovery pipelines of large pharmaceutical companies. The company Cambridge has become a major hub for monoclonal also has an academic access programme to collaborate with antibody technology and expertise that has encouraged leading experts interested in translating research from the several small companies working in this field to move to the bench to the clinic. Babraham Research Campus. Alongside Kymab, the campus REFERENCES also hosts Bicycle Therapeutics, Crescendo Biologics, Recombinant Antibody Technologies, and antibody 1 Kymab Ltd: http://www.kymab.com/ manufacturer Alpha Biologics5. 2 Kymouse technology: http://bit.ly/NBTkymouse The methods to produce monoclonal antibodies were first 3 Kmab Access: developed at the MRC Laboratory of Molecular Biology in http://www.kymabaccess.org Cambridge in the 1970s4. Further work at the MRC-LMB and 4 ‘New antibody specialist moves into Babraham’. Cambridge News. Available online: the Babraham Institute developed and refined the techniques http://www.cambridge-news.co.uk/Business/Business-News/New-antibody- required to produce human monoclonal antibodies. specialist-moves-into-Babraham.htm#ixzz2mVKiWw9x Health data 5 ‘Therapeutic antibodies and the LMB’. Available online: Image: fotolia Monoclonal antibodies are one of the best-selling classes http://www2.mrc-lmb.cam.ac.uk/antibody/ of drugs, largely because they work well and are generally 6 Press release ‘Babraham Bioscience Technologies celebrates the opening of an additional Bioincubator Building’: Kymab is the first company to spin out from research at The quite safe. They are biological drugs which bind to specific http://www.babraham.ac.uk/babraham-bioscience-technologies-celebrates- Wellcome Trust Sanger Institute near Hinxton in Cambridge. target molecules involved in the mechanisms that lead to the-opening-of-an-additional-bioincubator-building/ The company chose the Babraham Research Campus to base disease. The antibody targets can be on the surface of cells 7 See, for instance, the list at: http://en.wikipedia.org/wiki/List_of_monoclonal_antibodies its operations as the Campus provides high-quality research associated with disease, which can direct the immune system laboratories as well as the flexible capacity and services the to eliminate the diseased cell, or block the function of the company needs for its rapid growth3. Their location on the disease target molecule. Monoclonal antibodies are being Campus also allows Kymab to take advantage of Babraham’s used to treat a range of diseases including cancers and well-regarded animal welfare and ethical review process, autoimmune diseases such as rheumatoid arthritis6. ‘Fully overseen by researchers at the Babraham Institute. It also human’ monoclonal antibodies, such as those produced by enables Kymab to continue its close association with the Kymab, are designed to improve safety and effectiveness by Sanger Institute, which is only five miles from the Babraham avoiding unintended immune responses in patients. 2 Eagle Genomics Ltd ased on the Babraham Research Campus since early 2009, the bioinformatics company Eagle Genomics1 delivers products and services to answer the challenges associated with large-scale ‘omics’ Established in 2008, Eagle moved to the Babraham data and its application to
Recommended publications
  • Pooled CRISPR-Activation Screening Coupled with Single-Cell RNA-Seq in Mouse Embryonic Stem Cells

    Pooled CRISPR-Activation Screening Coupled with Single-Cell RNA-Seq in Mouse Embryonic Stem Cells

    ll OPEN ACCESS Protocol Pooled CRISPR-activation screening coupled with single-cell RNA-seq in mouse embryonic stem cells Celia Alda-Catalinas, Melanie A. Eckersley-Maslin, Wolf Reik celia.x.aldacatalinas@gsk. com (C.A.-C.) [email protected]. uk (W.R.) Highlights Protocol for CRISPRa screens with single- cell readout to interrogate gene function Detailed description of CRISPRa screening procedures in mouse embryonic stem cells Detailed steps on how to construct derived single-cell sgRNA amplicon libraries CRISPR/Cas9 screens are a powerful approach to identify key regulators of biological processes. By combining pooled CRISPR/Cas9 screening with a single-cell RNA-sequencing readout, individual perturbations can be assessed in parallel both comprehensively and at scale. Importantly, this allows gene function and regulation to be interrogated at a cellular level in an unbiased manner. Here, we present a protocol to perform pooled CRISPR-activation screens in mouse embryonic stem cells using 103 Genomics scRNA-seq as a readout. Alda-Catalinas et al., STAR Protocols 2, 100426 June 18, 2021 ª 2021 The Authors. https://doi.org/10.1016/ j.xpro.2021.100426 ll OPEN ACCESS Protocol Pooled CRISPR-activation screening coupled with single-cell RNA-seq in mouse embryonic stem cells Celia Alda-Catalinas,1,4,7,* Melanie A. Eckersley-Maslin,1,5,6 and Wolf Reik1,2,3,8,* 1Epigenetics Programme, Babraham Institute, Cambridge CB22 3AT, UK 2Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK 3Centre for Trophoblast Research, University of
  • Fulbourn Site Assessment Proforma

    Fulbourn Site Assessment Proforma

    South Cambridgeshire Strategic Housing Land Availability Assessment (SHLAA) Report August 2013 Appendix 7i: Assessment of 2011 'Call for Sites' SHLAA sites Index of Fulbourn Site Assessment Proforma Site Site Address Site Capacity Page Number Land at Fulbourn Old Drift (south of Site 037 Cambridge Road and north of Shelford 921 dwellings 766 Road), Fulbourn Site 038 Land north of Cambridge Road, Fulbourn 166 dwellings 775 Site 074 Land off Station Road, Fulbourn 186 dwellings 783 Site 108 Land south of Hinton Road, Fulbourn 52 dwellings 794 Land to the South of Fulbourn Old Drift & Site 109 78 dwellings 802 Hinton Road, Fulbourn Site 136 Land at Balsham Road, Fulbourn 62 dwellings 810 Land between Teversham Road and Cow Site 162 92 dwellings 818 Lane, Fulbourn Land at east of Court Meadows House, Site 213 166 dwellings 829 Balsham Road, Fulbourn Site 214 Land off Home End, Fulbourn 14 dwellings 837 Site 245 Bird Farm Field, Cambridge Road, Fulbourn 85 dwellings 845 SHLAA (August 2013) Appendix 7i – Assessment of 2011 ‘Call for Sites’ SHLAA sites Minor Rural Centre Fulbourn Page 765 South Cambridgeshire Local Development Framework Strategic Housing Land Availability Assessment (SHLAA) Site Assessment Proforma Proforma July 2012 Created Proforma Last July 2013 Updated Location Fulbourn Site name / Land at Fulbourn Old Drift (south of Cambridge Road and north of address Shelford Road), Fulbourn Category of A village extension i.e. a development adjoining the existing village site: development framework boundary Description of promoter’s 3,050 dwellings with public open space proposal Site area 76.78 ha. (hectares) Site Number 037 The site lies to the south of Cambridge Road and north of Shelford Road on the south western edge of Fulbourn.
  • The Oxford – Cambridge Arc Home of the New Innovation Economy

    The Oxford – Cambridge Arc Home of the New Innovation Economy

    Economic Vision: The Oxford – Cambridge Arc Home of the New Innovation Economy April 2019 Contents 1 Introduction 3 2 The Economic Vision 8 3 The New Innovation Economy: Sectors 11 4 The Innovation & Growth Network 24 5 Achieving Ambitions 29 6 Conclusion: Critical Mass 35 | Introduction 1 Introduction 1.1 This vision’s purpose The purpose of the Economic Vision is to explain the Oxford - Cambridge Arc’s unified proposition as a globally leading innovation and growth catalyst. The Arc offers access to each of the critical ingredients for business and innovation-led growth. This collective offer represents a powerful and coherent expression of the region’s current assets and future potential. This Economic Vision for the Arc sets out an ambition and series of proposals designed to unlock the economic potential of the region and deliver transformative growth for the UK between now and 2050. It provides a vision for how the Arc can better connect its unique and world-leading assets to become truly globally competitive in frontier markets, both for business investment and for top talent. With a bolder brand and stronger international presence the Arc can continue to lead the whole of the UK to the forefront of global innovation excellence in the coming years and decades. 3 | Introduction This Economic Vision is built upon the foundation of This Economic Vision has been developed in the four local industrial strategies which currently partnership with the three LEPs and the Combined demarcate the Arc’s geographic area. These have Authority, who have been given a mandate by Central been prepared by the Oxfordshire (OxLEP), South Government to drive forwards the Economic Vision for East Midlands (SEMLEP) and Buckinghamshire the Arc: Thames Valley (BTVLEP) Local Enterprise Partnerships, as well as the Cambridgeshire & Peterborough Mayoral Combined Authority (CPCA).
  • Minutes of the Proceedings

    Minutes of the Proceedings

    MINUTES OF THE PROCEEDINGS at the Thirty‐sixth Meeting of the COUNCIL of the IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE The Thirty‐sixth Meeting of the Council was held in the Council Room, 170 Queen’s Gate, South Kensington Campus, Imperial College London, at 10:00 a.m. on Friday, 16th May 2014, when there were present: The Baroness Manningham‐Buller (Chair), Professor A. Anandalingam, Mr. C. Brinsmead, Dame Ruth Carnall, Mrs. P. Couttie, Professor M.J. Dallman, Mr. P. Dilley, Mr. D. Goldsmith, Professor N. Gooderham, Professor Dame Julia Higgins, Professor D.P.A. Kelleher, Ms. J.R. Lomax, Professor J. Magee, Mr. J. Newsum, Mr. S. Newton, Ms. K. Owen, Mr. M. Sanderson, Professor J Stirling, the President & Rector and the Clerk to the Court and Council. Apologies Mr. I. Conn. MINUTES Council – 7th February 2014 1. The Minutes of the thirty‐fifth Meeting of the Council, held on Friday, 7th February 2014, were taken as read, confirmed and signed. CHAIR’S REPORT 2. The Chair advised members that, following his appointment as Chair of the Chelsea and Westminster Hospital NHS Foundation Trust, Sir Thomas Hughes‐Hallett had resigned as a co‐opted member of the Council on 11 February. PRESIDENT & RECTOR’S REPORT 3. The President & Rector reported that this year’s Imperial Festival, held on 9th and 10th May, had received many visitors at the South Kensington campus to enjoy the various demonstrations, talks 1 Council 16th May 2014 and other activities on offer. What had started as a relatively modest pilot project in 2012 to explore how Imperial College London might share its research with more people had now evolved into a large‐scale and prominent annual fixture in the College’s calendar.
  • Medical Research Council Annual Report and Accounts 2006/07 HC 93

    Medical Research Council Annual Report and Accounts 2006/07 HC 93

    06/07 Annual Report and Accounts © Crown Copyright 2006 The text in this document (excluding any Royal Arms and departmental logos) may be reproduced free of charge in any format or medium providing that it is reproduced accurately and not used in a misleading context. The material must be acknowledged as Crown copyright and the title of the document specified. Any queries relating to the copyright in this document should be addressed to The Licensing Division, HMSO, St Clements House, 2-16 Colegate, Norwich, NR3 1BQ. Fax: 01603 723000 or e-mail: licensing@cabinet-office.x.gsi.gov.uk 2 MRC Annual Report and Accounts 2006/07 Medical Research Council Annual Report and Accounts 2006/07 Presented to Parliament by the Secretary of State, and by the Comptroller and Auditor General in pursuance of Schedule I, Sections 2(2) and 3(3) of the Science and Technology Act 1965. Sir John Chisholm Chairman Professor Sir Leszek Borysiewicz Deputy Chairman and Chief Executive Ordered by and printed on London: The Stationery Office 6 February 2008 Price: £18.55 HC 93 The Medical Research Council The MRC RCUK The Medical Research Council (MRC) was set up in 1913 to administer Research Councils UK (RCUK) is a partnership of the seven (formerly public funds for medical research. It was incorporated under its eight) UK Research Councils – public bodies funded mainly by the UK present title by Royal Charter in 1920. A supplemental charter was Government via OSI. granted in 1993 describing the MRC’s new mission following the 1993 government white paper on science and technology.
  • Land at Hinxton Response to Matters and Issues Raised by the Inspector

    Land at Hinxton Response to Matters and Issues Raised by the Inspector

    M4/23548 Land at Hinxton Response to matters and issues raised by the Inspector Representation prepared by Terence O’Rourke on behalf of Hinxton Land Ltd Matter 4 Employment and retail c. Will the proposed amounts of land for economic development uses meet the needs for all foreseeable types of economic development? Summary 1. The employment land allocations will not meet all foreseeable types of economic development over the plan period. 2. The pressure for growth is significant to the South of Cambridge where most of the major high technology research facilities are located. 3. E/9 provides flexibility for delivering additional economic development over the plan period in the most sustainable locations and where businesses want to locate. These developments can be delivered in addition to, and in parallel with, the allocated sites over the plan period. Economic need and Policy E/9 During the consultation on the submission version of the local plan, Hinxton Land Ltd supported the inclusion of Policy E/9 (ID 60757, 60758) and Policy E/10 in principle (60759). These policies will facilitate the delivery of cluster-related economic development in sustainable locations during the plan period, which will help to maintain the Cambridge area as one of the leading concentrations of high technology and research clusters in the UK. Matter 4 c is relevant to these earlier representations prepared by Hinxton Land Ltd. We do not consider that the proposed amount of land allocated for economic development will meet the needs for all foreseeable types of economic development. Hinxton Land Ltd has not sought an allocation in the current plan, because policy E/9 provides policy support to deliver cluster-related development in sustainable locations, such as to the south of Cambridge on land beyond the green belt, in a flexible manner and in response to market demand.
  • Michael John Owen Wakelam 1955–2020

    Michael John Owen Wakelam 1955–2020

    obituary Michael John Owen Wakelam 1955–2020 We have lost a distinguished biochemist who dedicated his career to the study of phosphatidylinositol signalling in metabolic regulation and to the advancement of lipidomics. ichael John Owen Wakelam passed away on 31 March, 2020 at the Mage of 64, much too early. He became known to colleagues and friends as a scientist highly regarded for his research. He was honoured in 2018 with the Morton Lectureship of the Biochemical Society and was elected a fellow of the Royal Society of Biology. In 2019, he was elected a member of the Academia Europaea. Academic career It was not by chance that Michael turned his focus to phosphatidylinositols (PIs) and lipid signalling. He was a student and later a professor at the University of Birmingham at a time when Britain was the world’s hub of pioneering phospholipid research, such as that by J. N. Hawthorne and Bob Michell on PI in Birmingham. Bob Michell inspired Michael extraordinarily, and they even published a joint review. Subsequently, Michael moved to Cambridge to serve as the director of the Babraham Institute, where Credit: Babraham Institute Rex Dawson and Robin Irvine studied phospholipids, particularly PI metabolism and signalling. A joint publication by Michael and Irvine appeared as well. the Babraham Institute, and he received an the Keystone Symposia on Molecular and Certainly, Michael’s scientific engagement honorary professorship in lipid signalling at Cellular Biology. can be seen in the tradition of these eminent the University of Cambridge Clinical School. phospholipid scientists. In addition, he was an honorary professor Lipid signalling and metabolism Michael’s career path is impressive.
  • 24, 2021 Program Book Table of Contents

    24, 2021 Program Book Table of Contents

    June 21 – 24, 2021 Program Book Table of Contents Genetics Society of America . 3 Conference Organizers . 5 International C. elegans Board 2021 . 7 Sponsors . 9 Schedule of Events . 11 General Information . 16 Conference App . .. 17 Oral Presenters . 17 Poster Presenters . 17 Viewing Oral Sessions . 18 Attending Live Poster Sessions . .. 18 Live Poster Session Schedule . 19 Sponsor and Exhibitor Education Sessions . 21 Daily Meet-ups via Zoom and Remo . 22 Viewing Virtual Posters on the App . 23 Slack Chat Channels . 23 Job Postings . 23 Presenting Author Index . 23 Conference Policies . 24 Exhibits . 27 Oral Presentation and Workshop Session Listings . 29 Poster Session Listings . 58 23rd International C. elegans Conference | 2 Genetics Society of America Genetics Society of America GSA is an international scientific society representing more than 5,000 researchers and educators around the world. As well as connecting researchers through conferences and career programs, we publish two peer- edited scholarly journals, GENETICS and G3: Genes|Genomes|Genetics. We encourage you to join GSA so you can make use of exclusive member benefits and get involved in the Society’s many programs, including professional development training, awards, advocacy, and more. Join us as we work to advance the field and serve our community. Visit genetics-gsa.org for more information. GENETICS has been innovating since 1916, publishing high quality original research across the breadth of the field. G3: Genes|Genomes|Genetics is an open access journal that publishes high quality, useful results regardless of perceived impact. 2021 GSA Board of Directors Officers Directors Journal Editors Hugo Bellen, President Swathi Arur Brenda J.
  • Green Belt Study 2002

    Green Belt Study 2002

    South Cambridgeshire District Council South Cambridgeshire Hall 9-11 Hills Road Cambridge CB2 1PB CAMBRIDGE GREEN BELT STUDY A Vision of the Future for Cambridge in its Green Belt Setting FINAL REPORT Landscape Design Associates 17 Minster Precincts Peterborough PE1 1XX Tel: 01733 310471 Fax: 01733 553661 Email: [email protected] September 2002 1641LP/PB/SB/Cambridge Green Belt Final Report/September 2002 CONTENTS CONTENTS SUMMARY 1.0 INTRODUCTION 2.0 CAMBRIDGE GREEN BELT: PLANNING CONTEXT 3.0 METHODOLOGY 4.0 BASELINE STUDIES Drawings: 1641LP/01 Policy Context: Environmental Designations 1641LP/02 Policy Context: Cultural and Access Designations 1641LP/03 Topography 1641LP/04 Townscape Character 1641LP/05 Landscape Character 1641LP/06 Visual Assessment 5.0 SETTING AND SPECIAL CHARACTER Drawings: 1641LP/07 Townscape and Landscape Analysis 1641LP/08 Townscape and Landscape Role and Function 6.0 QUALITIES TO BE SAFEGUARDED AND A VISION OF THE CITY Drawings: 1641LP/09 Special Qualities to be Safeguarded 1641LP/10 A Vision of Cambridge 7.0 DETAILED APPRAISAL EAST OF CAMBRIDGE Drawings: 1641LP/11 Environment 1641LP/12 Townscape and Landscape Character 1641LP/13 Analysis 1641LP/14 Special Qualities to be Safeguarded 1641LP/15 A Vision of East Cambridge 8.0 CONCLUSIONS Cover: The background illustration is from the Cambridgeshire Collection, Cambridge City Library. The top illustration is the prospect of Cambridge from the east and the bottom illustration is the prospect from the west in 1688. 1641LP/PB/SB/Cambridge Green Belt Final Report/September 2002 SUMMARY SUMMARY Appointment and Brief South Cambridgeshire District Council appointed Landscape Design Associates to undertake this study to assess the contribution that the eastern sector of the Green Belt makes to the overall purposes of the Cambridge Green Belt.
  • Annual Report 2018

    Annual Report 2018

    Red RGB:165-29-47 CMYK: 20-99-82-21 Gold RGB: 226-181-116 CMYK: 16-46-91-1 Blue RGB: 39-47-146 CMYK: 92-86-1-0 Annual Report 2018 Published 12 June 2019 Ely Diocesan Board of Finance We pray to be generous and visible people of Jesus Christ. Nurture a confident people of God Develop healthy churches Serve the community Re-imagine our buildings Target support to key areas TO ENGAGE FULLY AND COURAGEOUSLY WITH THE NEEDS OF OUR COMMUNITIES, LOCALLY AND GLOBALLY TO GROW GOD’S CHURCH BY FINDING DISCIPLES AND NURTURING LEADERS TO DEEPEN OUR COMMITMENT TO GOD THROUGH WORD, WORSHIP AND PRAYER. ENGAGE • GROW • DEEPEN | 3 Contents 04 Foreword from Bishop Stephen 05 Ely2025 – A Review 06 Safeguarding 09 Ministry 11 Mothers' Union 12 Mission 15 Retreat Centre 16 Church Buildings and Pastoral Department 20 Secretariat 21 Programme Management Office 23 Changing Market Towns 24 Parish Giving Scheme 25 Contactless Giving (Card Readers) 26 Communications and Database 29 Education 32 Finance 34 Houses Sub-Committee 35 Diocesan Assets Sub-Committee 37 Ministry Share Tables 4 | ENGAGE • GROW • DEEPEN Foreword from Bishop Stephen As a Diocese we are seeking to be People Fully Alive, as we One of the most important ways in which we serve our pray to be generous and visible people of Jesus Christ. We communities is through the Diocesan family of schools, as we are seeking to do this as we engage with our communities educate over 15,000 children. These are challenging times for locally and globally, as we grow in faith, and as we deepen in the education sector and especially for small and rural schools.
  • Crp-Brochure-080518-Na-Web.Pdf

    Crp-Brochure-080518-Na-Web.Pdf

    Where Life Meets Science Where Life Meets Science “Research excellence is one of the The Park offers a flexible and fostering CHESTERFORD RESEARCH PARK Building on 60 years of continuous R&D at Chesterford is being developed as a 250 Foreword defining features of the Cambridge environment for both established R&D PROVIDES A SUPERBLY FLEXIBLE Chesterford, innovative biotechnology and acre low density scheme. To date, more landscape. Both academically and in companies and start-ups alike, providing AND FUTURE PROOFED pharmaceutical occupiers thrive in than 300,000 sq ft of laboratory and R&D the transfer of knowledge through to cutting-edge research facilities within a state-of-the-art accommodation and enjoy space has been let and occupied. Further ENVIRONMENT FOR BOTH EARLY commercial application, our region has community that encourages collaboration modern, central facilities, all set within a phases of construction are proposed to STAGE AND ESTABLISHED R&D established an international reputation at every stage. Chesterford Research Park unique and idyllic parkland location. extend the development to approximately that attracts outstanding academics, will help ensure that Cambridge ideas COMPANIES 1 million sq ft. researchers and business leaders who continue to change the world.” collectively drive discovery in so many different spheres. The depth and amazing Professor Sir Leszek Borysiewicz diversity of that research capability is Vice-Chancellor of the University of Cambridge. apparent at Chesterford Research Park. (Retired 2017)
  • Trends and Challenges in Computational RNA Biology Alina Selega and Guido Sanguinetti*

    Trends and Challenges in Computational RNA Biology Alina Selega and Guido Sanguinetti*

    Selega and Sanguinetti Genome Biology (2016) 17:253 DOI 10.1186/s13059-016-1117-7 MEETINGREPORT Open Access Trends and challenges in computational RNA biology Alina Selega and Guido Sanguinetti* Abstract complemented by two lively poster sessions, where partic- ipants had an opportunity to engage with over 40 posters A report on the Wellcome Trust Conference on during evening drinks receptions. Computational RNA Biology, held in Hinxton, UK, on In this report, we briefly recount the content of the 17–19 October 2016. conference by providing condensed, headline-style sum- Keywords: RNA, Review, Computational biology maries of the research described in the talks and some posters. Within the scope of this brief report, we cannot possibly do justice to the wealth and breadth of material Introduction presented and we will not be able to mention much inter- Recent years have witnessed a profound shift in our esting research, particularly within the poster sessions. understanding of RNA biology. Several novel biochemical We would like to stress that omissions in this report are and sequencing techniques are producing vast amounts not based on quality, but simply on a personal judgement of data that fundamentally challenge the textbook view as to what material could be most coherently presented in of RNA as a simple intermediate step of gene expression, a very limited space. revealing a wealth of unexpected new roles and shed- ding light on the complexity of the RNA world. While Transcripts the emerging picture unequivocally points to the cen- Perhaps the most remarkable discovery in modern RNA trality of RNA as a mediator of most cellular functions, biology is the realization of the diversity of the transcrip- the richness and heterogeneity of modern datasets pose tome.